This article discloses the compositions and methods that involve or originate from anti JAG1 antibodies. More specifically, the JAG1 binding fragments and derivatives of such antibodies and the JAG1 binding polypeptides containing such fragments are disclosed in combination with JAG1's holistic antibodies. In addition, this paper discloses nucleic acid encoding such antibodies, antibody fragments and derivatives, and polypeptides, polynucleotides containing such cells, preparation method of such antibodies, antibody fragments and derivatives, and polypeptides, and methods of using such antibodies, antibody fragments and derivatives, and peptides, including methods of treating or a diagnosis of JAG1 related disorders or disorders of subjects. This paper also disclosed for the treatment of JAG1 expressing tumors (including hepatocellular carcinoma and squamous cell carcinoma), and induced from rheumatoid arthritis, experimental lung injury, atherosclerosis, hepatitis C virus of chronic liver disease, ischemic myocardial injury and heart failure in non oncology diseases.
【技术实现步骤摘要】
【国外来华专利技术】结合JAG1的抗体治疗剂相关应用本申请要求2015年3月6日提交的美国临时申请号62/129,180的优先权,其全部内容通过引用整体并入本文。
本专利技术提供涉及或源自抗JAG1抗体的组合物和方法。更具体地,本专利技术提供结合JAG1的全人抗体,这样的抗体的JAG1抗体结合片段和衍生物,以及包含这样的片段的JAG1结合多肽。此外,本专利技术提供编码这样的抗体、抗体片段和衍生物、和多肽的核酸,包含这样的多核苷酸的细胞,制备这样的抗体、抗体片段和衍生物、和多肽的方法,以及使用这样的抗体、抗体片段和衍生物、和多肽的方法,包括治疗或诊断具有JAG1相关障碍或病症的受试者的方法。本专利技术还提供用于治疗Notch信号传导肿瘤(包括乳腺、前列腺、结直肠、肺和其他实体肿瘤)的方法。
技术介绍
Notch信号传导通路是胚胎模式形成、胚胎后组织维持和干细胞生物学的多个关键调节因子之一。更具体地,Notch信号传导参与相邻细胞命运之间的侧向抑制过程,并且在不对称细胞分裂期间的细胞命运决定中起到重要作用。未经调节的Notch信号传导与许多人类癌症相关,其中其可以改变肿瘤细胞的发育命运以使它们保持在未分化和增殖状态(Brennan和Brown,2003,BreastCancerRes.5:69)。因此,通过侵害控制干细胞群体的正常发育和组织修复的稳态机制,癌发生可以推进(Beachy等,2004,Nature432:324)。Notch受体首先在具有在翅膀边缘处产生缺口的单倍不足的果蝇突变体中识别出,然而功能丧失产生胚胎致死性“神经源性”表型,其中表皮的细胞命运转换为神经组织(M ...
【技术保护点】
一种结合JAG1表位的IgG种类的分离的抗JAG1全人抗体,所述抗体包含:重链可变结构域序列,所述重链可变结构域序列与选自以下的氨基酸序列至少95%相同:SEQ ID NO.1,SEQ ID NO.3,SEQ ID NO.5,SEQ ID NO.7,SEQ ID NO.9,SEQ ID NO.11,SEQ ID NO.13,SEQ ID NO.15,SEQ ID NO.17,SEQ ID NO.19,SEQ ID NO.21,SEQ ID NO.23,SEQ ID NO.25,SEQ ID NO.27,SEQ ID NO.29,SEQ ID NO.31,SEQ ID NO.33,SEQ ID NO.35,SEQ ID NO.37,SEQ ID NO.39,SEQ ID NO.41,SEQ ID NO.43,SEQ ID NO.45,SEQ ID NO.47,SEQ ID NO.49,SEQ ID NO.51,SEQ ID NO.53,SEQ ID NO.55,SEQ ID NO.57,SEQ ID NO.59,SEQ ID NO.61,SEQ ID NO.63,SEQ ID NO.65 ...
【技术特征摘要】
【国外来华专利技术】2015.03.06 US 62/129,1801.一种结合JAG1表位的IgG种类的分离的抗JAG1全人抗体,所述抗体包含:重链可变结构域序列,所述重链可变结构域序列与选自以下的氨基酸序列至少95%相同:SEQIDNO.1,SEQIDNO.3,SEQIDNO.5,SEQIDNO.7,SEQIDNO.9,SEQIDNO.11,SEQIDNO.13,SEQIDNO.15,SEQIDNO.17,SEQIDNO.19,SEQIDNO.21,SEQIDNO.23,SEQIDNO.25,SEQIDNO.27,SEQIDNO.29,SEQIDNO.31,SEQIDNO.33,SEQIDNO.35,SEQIDNO.37,SEQIDNO.39,SEQIDNO.41,SEQIDNO.43,SEQIDNO.45,SEQIDNO.47,SEQIDNO.49,SEQIDNO.51,SEQIDNO.53,SEQIDNO.55,SEQIDNO.57,SEQIDNO.59,SEQIDNO.61,SEQIDNO.63,SEQIDNO.65,SEQIDNO.67,SEQIDNO.69,SEQIDNO.71,SEQIDNO.73,SEQIDNO.75,SEQIDNO.77,SEQIDNO.79,SEQIDNO.81,SEQIDNO.83,SEQIDNO.85,SEQIDNO.87,SEQIDNO.89,SEQIDNO.91,SEQIDNO.93,SEQIDNO.95,SEQIDNO.97,SEQIDNO.99,SEQIDNO.101,SEQIDNO.103,SEQIDNO.105,SEQIDNO.107,SEQIDNO.109,SEQIDNO.111,SEQIDNO.124,SEQIDNO.125,SEQIDNO.126,SEQIDNO.127,SEQIDNO.128,SEQIDNO.129,SEQIDNO.130,SEQIDNO.132,SEQIDNO.135,SEQIDNO.139和SEQIDNO.142;和轻链可变结构域序列,所述轻链可变结构域序列与选自以下的氨基酸序列至少95%相同:SEQIDNO.2,SEQIDNO.4,SEQIDNO.6,SEQIDNO.8,SEQIDNO.10,SEQIDNO.12,SEQIDNO.14,SEQIDNO.16,SEQIDNO.18,SEQIDNO.20,SEQIDNO.22,SEQIDNO.24,SEQIDNO.26,SEQIDNO.28,SEQIDNO.30,SEQIDNO.32,SEQIDNO.34,SEQIDNO.36,SEQIDNO.38,SEQIDNO.40,SEQIDNO.42,SEQIDNO.44,SEQIDNO.46,SEQIDNO.48,SEQIDNO.50,SEQIDNO.52,SEQIDNO.54,SEQIDNO.56,SEQIDNO.58,SEQIDNO.60,SEQIDNO.62,SEQIDNO.64,SEQIDNO.66,SEQIDNO.68,SEQIDNO.70,SEQIDNO.72,SEQIDNO.74,SEQIDNO.76,SEQIDNO.78,SEQIDNO.80,SEQIDNO.82,SEQIDNO.84,SEQIDNO.86,SEQIDNO.88,SEQIDNO.90,SEQIDNO.92,SEQIDNO.94,SEQIDNO.96,SEQIDNO.98,SEQIDNO.100,SEQIDNO.102,SEQIDNO.104,SEQIDNO.106,SEQIDNO.108,SEQIDNO.110,SEQIDNO.112,SEQIDNO.113,SEQIDNO.114,SEQIDNO.115,SEQIDNO.116,SEQIDNO.117,SEQIDNO.118,SEQIDNO.119,SEQIDNO.120,SEQIDNO.121,SEQIDNO.122,SEQIDNO.123,SEQIDNO.131,SEQIDNO.133,SEQIDNO.134,SEQIDNO.136,SEQIDNO.137,SEQIDNO.138,SEQIDNO.140和SEQIDNO.141。2.权利要求1所述的全人抗体,其中所述抗体包含选自以下的重链/轻链可变结构域序列:SEQIDNO.1/SEQIDNO.2(JG1A1),SEQIDNO.3/SEQIDNO.4(JG1A10),SEQIDNO.5/SEQIDNO.6(JG1A12),SEQIDNO.7/SEQIDNO.8(JG1A3),SEQIDNO.9/SEQIDNO.10(JG1A4),SEQIDNO.11/SEQIDNO.12(JG11A5),SEQIDNO.13/SEQIDNO.14(JG1A6),SEQIDNO.15/SEQIDNO.16(JG1A7),SEQIDNO.17/SEQIDNO.18(JG1B1),SEQIDNO.19/SEQIDNO.20(JG1B10),SEQIDNO.21/SEQIDNO.22(JG1B11),SEQIDNO.23/SEQIDNO.24(JG1B12),SEQIDNO.25/SEQIDNO.26(JG1B4),SEQIDNO.27/SEQIDNO.28(JG1B5),SEQIDNO.29/SEQIDNO.30(JG1B6),SEQIDNO.31/SEQIDNO.32(JG1B8),SEQIDNO.33/SEQIDNO.34(JG1C3),SEQIDNO.35/SEQIDNO.36(JG1C4),SEQIDNO.37/SEQIDNO.38(JG1C5),SEQIDNO.39/SEQIDNO.40(JG1C8),SEQIDNO.41/SEQIDNO.42(JG1D1),SEQIDNO.43/SEQIDNO.44(JG1D10),SEQIDNO.45/SEQIDNO.46(JG1D11),SEQIDNO.47/SEQIDNO.48(JG1D7),SEQIDNO.49/SEQIDNO.50(JG1D8),SEQIDNO.51/SEQIDNO.52(JG1E1),SEQIDNO.53/SEQIDNO.54(JG1E11),SEQIDNO.55/SEQIDNO.56(JG1E7),SEQIDNO.57/SEQIDNO.58(JG1E8),SEQIDNO.59/SEQIDNO.60(JG1F1),SEQIDNO.61/SEQIDNO.62(JG1F10),SEQIDNO.63/SEQIDNO.64(JG1F7),SEQIDNO.65/SEQIDNO.66(JG1F8),SEQIDNO.67/SEQIDNO.68(JG1G11),SEQIDNO.69/SEQIDNO.70(JG1G5),SEQIDNO.71/SEQIDNO.72(JG1H1),SEQIDNO.73/SEQIDNO.74(JG1H11),SEQIDNO.75/SEQIDNO.76(JG1H5),SEQIDNO.77/SEQIDNO.78(JG1H7),SEQIDNO.79/SEQIDNO.80(JH1A1),SEQIDNO.81/SEQIDNO.82(JH1A11),SEQIDNO.83/SEQIDNO.84(JH1A2),SEQIDNO.85/SEQIDNO.86(JH1A4),SEQIDNO.87/SEQIDNO.88(JH1B1n),SEQIDNO.89/SEQIDNO.90(JH1B3),SEQIDNO.91/SEQIDNO.92(JH1B7),SEQIDNO.93/SEQIDNO.94(JH1C10),SEQIDNO.95/SEQIDNO.96(JH1C2),SEQIDNO.97/SEQIDNO.98(JH1D7),SEQIDNO.99/SEQIDNO.100(JH1E11),SEQIDNO.101/SEQIDNO.102(JH1F3),SEQIDNO.103/SEQIDNO.104(JH1F4),SEQIDNO.105/SEQIDNO.106(JH1F6),SEQIDNO.107/SEQIDNO.108(JH1H2),SEQIDNO.109/SEQIDNO.110(JH1H7),SEQIDNO.111/SEQIDNO.112(G1H73-2),SEQIDNO.111/SEQIDNO.113(JG1H7-2B2S),SEQIDNO.111/SEQIDNO.114(JG1H7-2AS),SEQIDNO.111/SEQIDNO.115(JG1H73-2A7S),SEQIDNO.111/SEQIDNO.116(JG1H7-2A10S),SEQIDNO.111/SEQIDNO.117(JG1H7-2A2S),SEQIDNO.111/SEQIDNO.118(JG1H73-2A9S),SEQIDNO.111/SEQIDNO.119(JG1H7-2A1S),SEQIDNO.111/SEQIDNO.120(JG1H7-E11S),SEQIDNO.111/SEQIDNO.121(JG1H73-C11S),SEQIDNO.111/SEQIDNO.122(JG1H7-D10S),SEQIDNO.111/SEQIDNO.123(JG1H7-2B7S),SEQIDNO.124/SEQIDNO.112(JG1H7-1A8S),SEQIDNO.125/SEQIDNO.112(JG1H73-1A6S),SEQIDNO.126/SEQIDNO.112(JG1H7-1A2S),SEQIDNO.127/SEQIDNO.112(JG1H7-1B1S),SEQIDNO.128/SEQIDNO.112(JG1H73-1A8S),SEQIDNO.129/SEQIDNO.112(JG1H7-5B5S),SEQIDNO.130/SEQIDNO.112(JG1H7-3E5S),SEQIDNO.127/SEQIDNO.131(JG1H7-G6C),SEQIDNO.132/SEQIDNO.133(JG1H73-A6C),SEQIDNO.132/SEQIDNO.123(JG1H7-E11C),SEQIDNO.142/SEQIDNO.123(JG1H7-C6C),SEQIDNO.127/SEQIDNO.123(JG1H73-C9C),SEQIDNO.132/SEQIDNO.134(JG1H7-F4C),SEQIDNO.135/SEQIDNO.133(JG1H7-F2C),SEQIDNO.132/SEQIDNO.136(JG1H7-F1C),SEQIDNO.132/SEQIDNO.137(JG1H7-D4C),SEQIDNO.132/SEQIDNO.138(JG1H73-D5C),SEQIDNO.139/SEQIDNO.123(JG1H7-A5C),SEQIDNO.139/SEQIDNO.140(JG1H7-B2C)和SEQIDNO.127/SEQIDNO.141(JG1H73-B6C)。3.权利要求1或2所述的全人抗体,其中所述抗体具有至少1×10-6M的KD。4.一种抗JAG1全人抗体Fab片段,其包含重链可变结构域,所述重链可变结构域包含与选自以下的氨基酸序列至少95%相同的氨基酸序列:SEQIDNO.1,SEQIDNO.3,SEQIDNO.5,SEQIDNO.7,SEQIDNO.9,SEQIDNO.11,SEQIDNO.13,SEQIDNO.15,SEQIDNO.17,SEQIDNO.19,SEQIDNO.21,SEQIDNO.23,SEQIDNO.25,SEQIDNO.27,SEQIDNO.29,SEQIDNO.31,SEQIDNO.33,SEQIDNO.35,SEQIDNO.37,SEQIDNO.39,SEQIDNO.41,SEQIDNO.43,SEQIDNO.45,SEQIDNO.47,SEQIDNO.49,SEQIDNO.51,SEQIDNO.53,SEQIDNO.55,SEQIDNO.57,SEQIDNO.59,SEQIDNO.61,SEQIDNO.63,SEQIDNO.65,SEQIDNO.67,SEQIDNO.69,SEQIDNO.71,SEQIDNO.73,SEQIDNO.75,SEQIDNO.77,SEQIDNO.79,SEQIDNO.81,SEQIDNO.83,SEQIDNO.85,SEQIDNO.87,SEQIDNO.89,SEQIDNO.91,SEQIDNO.93,SEQIDNO.95,SEQIDNO.97,SEQIDNO.99,SEQIDNO.101,SEQIDNO.103,SEQIDNO.105,SEQIDNO.107,SEQIDNO.109,SEQIDNO.111,SEQIDNO.124,SEQIDNO.125,SEQIDNO.126,SEQIDNO.127,SEQIDNO.128,SEQIDNO.129,SEQIDNO.130,SEQIDNO.132,SEQIDNO.135,SEQIDNO.139和SEQIDNO.142;并且包含轻链可变结构域,所述轻链可变结构域包含与选自以下的氨基酸序列至少95%相同的氨基酸序列:SEQIDNO.2,SEQIDNO.4,SEQIDNO.6,SEQIDNO.8,SEQIDNO.10,SEQIDNO.12,SEQIDNO.14,SEQIDNO.16,SEQIDNO.18,SEQIDNO.20,SEQIDNO.22,SEQIDNO.24,SEQIDNO.26,SEQIDNO.28,SEQIDNO.30,SEQIDNO.32,SEQIDNO.34,SEQIDNO.36,SEQIDNO.38,SEQIDNO.40,SEQIDNO.42,SEQIDNO.44,SEQIDNO.46,SEQIDNO.48,SEQIDNO.50,SEQIDNO.52,SEQIDNO.54,SEQIDNO.56,SEQIDNO.58,SEQIDNO.60,SEQIDNO.62,SEQIDNO.64,SEQIDNO.66,SEQIDNO.68,SEQIDNO.70,SEQIDNO.72,SEQIDNO.74,SEQIDNO.76,SEQIDNO.78,SEQIDNO.80,SEQIDNO.82,SEQIDNO.84,SEQIDNO.86,SEQIDNO.88,SEQIDNO.90,SEQIDNO.92,SEQIDNO.94,SEQIDNO.96,SEQIDNO.98,SEQIDNO.100,SEQIDNO.102,SEQIDNO.104,SEQIDNO.106,SEQIDNO.108,SEQIDNO.110,SEQIDNO.112,SEQIDNO.113,SEQIDNO.114,SEQIDNO.115,SEQIDNO.116,SEQIDNO.117,SEQIDNO.118,SEQIDNO.119,SEQIDNO.120,SEQIDNO.121,SEQIDNO.122,SEQIDNO.123,SEQIDNO.131,SEQIDNO.133,SEQIDNO.134,SEQIDNO.136,SEQIDNO.137,SEQIDNO.138,SEQIDNO.140和SEQIDNO.141。5.权利要求4所述的全人抗体Fab片段,其中所述抗体包含选自以下的重链/轻链可变结构域序列:SEQIDNO.1/SEQIDNO.2,SEQIDNO.3/SEQIDNO.4,SEQIDNO.5/SEQIDNO.6,SEQIDNO.7/SEQIDNO.8,SEQIDNO.9/SEQIDNO.10,SEQIDNO.11/SEQIDNO.12,SEQIDNO.13/SEQIDNO.14,SEQIDNO.15/SEQIDNO.16,SEQIDNO.17/SEQIDNO.18,SEQIDNO.19/SEQIDNO.20,SEQIDNO.21/SEQIDNO.22,SEQIDNO.23/SEQIDNO.24,SEQIDNO.25/SEQIDNO.26,SEQIDNO.27/SEQIDNO.28,SEQIDNO.29/SEQIDNO.30,SEQIDNO.31/SEQIDNO.32,SEQIDNO.33/SEQIDNO.34,SEQIDNO.35/SEQIDNO.36,SEQIDNO.37/SEQIDNO.38,SEQIDNO.39/SEQIDNO.40,SEQIDNO.41/SEQIDNO.42,SEQIDNO.43/SEQIDNO.44,SEQIDNO.45/SEQIDNO.46,SEQIDNO.47/SEQIDNO.48,SEQIDNO.49/SEQIDNO.50,SEQIDNO.51/SEQIDNO.52,SEQIDNO.53/SEQIDNO.54,SEQIDNO.55/SEQIDNO.56,SEQIDNO.57/SEQIDNO.58,SEQIDNO.59/SEQIDNO.60,SEQIDNO.61/SEQIDNO.62,SEQIDNO.63/SEQIDNO.64,SEQIDNO.65/SEQIDNO.66,SEQIDNO.67/SEQIDNO.68,SEQIDNO.69/SEQIDNO.70,SEQIDNO.71/SEQ...
【专利技术属性】
技术研发人员:B·A·斯汪森,A·特里,E·格罗斯,周贺钺,
申请(专利权)人:索伦托治疗有限公司,
类型:发明
国别省市:美国,US
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。